Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that regularly issues updates on its cardiac monitoring platform, regulatory milestones, and commercialization plans. Company news highlights its focus on transforming cardiac care through portable, cable-free ECG technologies that can be used by adult patients in clinical settings or at home for arrhythmia assessment.
News releases frequently cover developments related to HeartBeam’s 3D ECG technology and 12-lead ECG synthesis software. These include FDA 510(k) clearance for arrhythmia assessment, the regulatory path for the 12-lead synthesis software, and the company’s responses to a Not Substantially Equivalent (NSE) decision and subsequent successful appeal. Investors can also find updates on clinical studies such as the VALID-ECG study and deep learning research presented at conferences like HRX Live, which examine how HeartBeam’s algorithms perform in detecting atrial fibrillation, atrial flutter, and sinus rhythm.
HeartBeam’s news flow also addresses commercial readiness, including plans for limited U.S. launch with concierge and preventive cardiology practices, establishment of a cardiology reader service, and infrastructure for customer service, contract manufacturing, and logistics. Announcements about the partnership with HeartNexus, Inc. describe how synthesized 12-lead ECGs from HeartBeam’s system will be reviewed by a network of board-certified cardiologists, supporting arrhythmia assessment and patient triage outside traditional healthcare facilities.
In addition, periodic earnings releases and conference participation notices provide insight into the company’s operating expenses, cash position, and engagement with investors and industry partners. Visitors to this news page can review these updates to understand how HeartBeam is progressing on regulatory, clinical, and commercialization objectives for its cardiac monitoring technologies.
HeartBeam (NASDAQ: BEAT) reported Q4 and full-year 2025 results and commercial progress. Key milestones include FDA 510(k) clearance (Dec 2025) for a cable-free synthesized 12-lead ECG, a first commercial partnership with ClearCardio, enrollment in the ALIGN-ACS pilot, and a working prototype of a 12-lead extended-wear ECG patch.
Financials: cash $4.4M at Dec 31, 2025; Q4 net loss $5.3M; full-year net loss $21.0M; R&D 2025 $13.5M. Management hosted a webcast March 12, 2026.
HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai to co-develop and validate next‑generation AI‑ECG algorithms using HeartBeam’s 3D ECG platform.
The partnership aims to train AI on longitudinal, synthesized 12‑lead ECGs captured at home to enable personalized, clinically relevant cardiac assessments and expand clinical indications and reimbursement pathways.
HeartBeam (NASDAQ: BEAT) said management will attend investor and industry conferences in March 2026 to provide commercial-launch updates and product demonstrations.
Key events: Oppenheimer MedTech & Services (virtual) March 16-17 with a March 16 webcast; ROTH Conference (Dana Point) March 23-24; ACC.26 (New Orleans) March 28-30 with booth #209. The FDA-cleared HeartBeam System will be demoed and a working 12-lead ECG extended wear patch prototype (not FDA-approved) will be shown to physicians and partners.
HeartBeam (NASDAQ: BEAT) announced first patient enrollments in the ALIGN-ACS pilot study for heart attack detection on March 5, 2026. The study will compare HeartBeam’s 3D ECG device with standard 12-lead ECGs in ER chest-pain patients to inform a multicenter pivotal study and potential FDA indication expansion.
The pilot aims to enroll 100 ER chest-pain patients, build on prior 3D ECG proof-of-concept results, and accelerate symptom-to-door assessment by enabling clinical-grade ECG capture outside hospitals.
HeartBeam (NASDAQ: BEAT) will host a conference call on Thursday, March 12, 2026 at 4:30 p.m. Eastern to discuss fourth-quarter and full-year 2025 results and strategic updates on the 12-lead ECG extended wear patch. A presentation and short video will accompany the webcast and will be available afterward in investor relations.
HeartBeam (NASDAQ: BEAT) announced its first commercial customer: ClearCardio, a preventive cardiology practice that will integrate HeartBeam’s synthesized 12-lead ECG technology into its member prevention programs.
The agreement is an initial staged rollout under a Letter of Intent, includes a planned ClearCardio investment, targets replication across concierge and executive health networks, and references a structured direct-pay segment representing 5 million patients.
HeartBeam (NASDAQ: BEAT) appointed Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. Humbarger brings more than 25 years of commercial leadership in cardiovascular and MedTech firms and will lead the company’s commercialization for its recently FDA-cleared 12-lead ECG system for arrhythmia assessment. His remit includes directing a limited launch, developing partnerships with channel partners and cardiology practices, validating real-world performance through reference sites, and advancing initiatives for heart attack detection and a 12-lead extended-wear ECG patch.
This role is newly created to scale commercial strategy and execute initial market introduction while building sales and clinical support infrastructure.
HeartBeam (NASDAQ: BEAT) will attend the JP Morgan 2026 Annual Healthcare Conference on January 12-15, 2026 with management available for off-site meetings January 12-14. The company announced it recently received FDA 510(k) clearance for a first-ever cable-free synthesized 12-lead ECG for at-home arrhythmia assessment that captures signals in three non-coplanar dimensions and synthesizes a 12-lead ECG. Readings are reviewed by an on-demand, board-certified cardiologist. HeartBeam plans a limited U.S. commercial launch in Q1 2026 with select concierge and preventive cardiology practices that signaled adoption interest. The company said broader rollout, wearable integration, AI-enabled insights, and its heart attack detection program will be announced later.
HeartBeam (NASDAQ: BEAT) announced FDA 510(k) clearance for its cable-free synthesized 12-lead ECG software for at-home arrhythmia assessment on December 10, 2025, following a successful appeal of a prior Not Substantially Equivalent determination. The device captures 3D cardiac signals and synthesizes a clinical-grade 12-lead ECG, with readings reviewed by on-demand board-certified cardiologists.
The company plans a limited U.S. launch in Q1 2026 targeting concierge and preventive cardiology groups, and intends to advance heart attack detection efforts, an extended-wear 12-lead patch prototype, and longitudinal AI screening built on its 3D ECG data.
HeartBeam (NASDAQ: BEAT) provided an update on its regulatory path after receiving a Not Substantially Equivalent (NSE) decision from the FDA for its 12‑lead ECG Synthesis Software on November 26, 2025. The company says its supporting clinical study (VALID‑ECG) met agreed endpoints and believes outstanding FDA concerns can be addressed via labeling modifications. HeartBeam is pursuing multiple parallel options, including an appeal or 510(k) resubmission, and the firm says recent FDA discussions indicate a constructive path forward. The company notes the official appeal timeline is approximately 60 days from submission to resolution and will provide updates on commercial launch and funding plans.